Cargando…

Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study

Accruing evidence suggests an increased risk of myocarditis in adolescents from messenger RNA COVID-19 vaccines. However, other potential adverse events remain under-researched. We conducted a retrospective cohort study of adolescents aged 12–18 with a territory-wide electronic healthcare database o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Francisco Tsz Tsun, Chua, Gilbert T., Chan, Edward Wai Wa, Huang, Lei, Kwan, Mike Yat Wah, Ma, Tiantian, Qin, Xiwen, Chui, Celine Sze Ling, Li, Xue, Wan, Eric Yuk Fai, Wong, Carlos King Ho, Chan, Esther Wai Yin, Wong, Ian Chi Kei, Ip, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942549/ https://www.ncbi.nlm.nih.gov/pubmed/35254219 http://dx.doi.org/10.1080/22221751.2022.2050952

Ejemplares similares

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
por: Chua, Gilbert T., et al.
Publicado: (2022)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2022)

Effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5–17
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2023)

Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study
por: Chan, Edward Wai Wa, et al.
Publicado: (2022)

The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
por: Cheng, Franco Wing Tak, et al.
Publicado: (2022)

Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study
por: Fan, Min, et al.
Publicado: (2023)

Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case–control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
por: Yang, Su Lan, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
por: Ripabelli, Giancarlo, et al.
Publicado: (2023)

Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested case-control study
por: Ye, Xuxiao, et al.
Publicado: (2023)

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
por: Hickey, Thomas E., et al.
Publicado: (2023)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
por: Katoto, Patrick DMC., et al.
Publicado: (2023)

Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Saliva viral load better correlates with clinical and immunological profiles in children with coronavirus disease 2019
por: Chua, Gilbert T., et al.
Publicado: (2021)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
por: Kyaw, Moe H., et al.
Publicado: (2023)

Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Co-circulation of two SARS-CoV-2 variant strains within imported pet hamsters in Hong Kong
por: Kok, Kin-Hang, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections
por: Tso, Winnie W.Y., et al.
Publicado: (2022)

Adverse event reporting and Bell's palsy risk after COVID-19 vaccination – Authors' reply
por: Wong, Ian Chi Kei, et al.
Publicado: (2021)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
por: Naito, Toshio, et al.
Publicado: (2021)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients
por: Higashimoto, Yuki, et al.
Publicado: (2022)

Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study
por: Chui, Celine Sze Ling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k2ult4cqe1n85j2nu8mtsjmro6